ArticleDigestive diseases and sciences2026
Endoscopic Application of GM-CSF, Fosfomycin, and Metronidazole in Pouchitis, a Phase I Safety and Pilot Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04979832 (A Combined Treatment With GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative Ileal Pouch Anal Anastomosis Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Combined Treatment With GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative Ileal Pouch Anal Anastomosis Surgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation of the pouch is common in patients with ulcerative colitis after ileal pouch anal anastomosis surgery. Up to 20% of patients develop chronic or treatment refractory pouchitis.
aimsWe aimed to test the safety and efficacy of applying a combination drug in the pouch.
methodsWe conducted a single-arm, open-label phase I study. Patients with pouchitis received a single dose of 50 µg granulocyte-macrophage colony-stimulating factor (GM-CSF), 400 mg of fosfomycin, and 100 mg of metronidazole endoscopically in the pouch. The primary outcome was the occurrence of adverse events, while secondary outcomes were changes in the Pouchitis Disease Activity Index (PDAI), laboratory parameters, bacterial composition, and mucosal gene expression patterns.
resultsSix patients were included from August 2021 to December 2022 at Zealand University Hospital. One serious adverse event occurred in the form of a hospitalization for dehydration, deemed unrelated to the study drug. PDAI decreased on average 2 points, with 2 (33.3%) patients achieving clinical remission (PDAI < 7), while laboratory parameters remained similar. Bacterial composition of the pouch mucosa did not change significantly. Gene expression analysis indicated enhanced immune cell communication, reduced proteasome activity, and a shift from innate to adaptive immunity, with fewer dendritic cells and more B cells in the pouch mucosa after treatment.
conclusionsThe administration of GM-CSF, fosfomycin, and metronidazole in the pouch appears to be safe in patients with pouchitis and results in immunological changes suggesting a reduction in inflammation, ClincialTrials.gov number, NCT04979832.
Indexed as
Identifiers
42728546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.